Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
04 Junho 2024 - 5:05PM
Business Wire
Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical stage
biopharmaceutical company focused on discovering and developing
novel, oral small molecule therapies that target biological
pathways associated with specific clinical impairments for the
treatment of neuroscience, inflammation and immunology (NI&I)
indications, today announced that Company management will
participate in the 45th Annual Goldman Sachs Healthcare Conference,
taking place June 10-13, 2024 in Miami.
Carmine Stengone, President and Chief Executive Officer of
Contineum, will participate in a fireside chat on Monday, June 10,
2024 at 8:40 am Eastern Time, and management will host one-on-one
meetings with investors.
A live webcast of the fireside chat will be available on the
Investors section of Contineum’s website and a replay will be
available following the conclusion of the event.
About Contineum Therapeutics
Contineum Therapeutics (Nasdaq: CTNM) is a clinical stage
biopharmaceutical company focused on discovering and developing
novel, oral small molecule therapies for NI&I indications with
high unmet need. Contineum is focused on targeting biological
pathways associated with specific clinical impairments, that
Contineum believes, once modulated, may demonstrably impact the
course of disease. Contineum has a pipeline of internally-developed
programs to address multiple NI&I disorders. PIPE-791 is an
LPA1 receptor antagonist which recently completed a Phase 1 healthy
volunteer clinical trial to support ongoing clinical development
for IPF and progressive multiple sclerosis. PIPE-307, a selective
inhibitor of the M1 receptor, is currently in a Phase 2 clinical
trial for relapse-remitting multiple sclerosis, and a Phase 2 trial
in depression is planned to initiate in 2024. Contineum is
developing PIPE-307 in collaboration with Johnson & Johnson
Innovative Medicines.
Contineum is headquartered in San Diego, CA. For more
information, please visit www.contineum-tx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240604132442/en/
Peter Slover CFO pslover@contineum-tx.com
IR@contineum-tx.com
Contineum Therapeutics (NASDAQ:CTNM)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Contineum Therapeutics (NASDAQ:CTNM)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
